Background: It is unclear whether publicly reporting hospitals' risk-adjusted mortality affects market share and mortality at outlier hospitals.
Objectives: To examine hospitals' market share and risk-adjusted mortality from 1991 to 1997 at hospitals participating in Cleveland Health Quality Choice (CHQC).
Research Design: Time series.
Subjects: Changes in market share were examined for all patients hospitalized with acute myocardial infarction, heart failure, gastrointestinal hemorrhage, obstructive pulmonary disease, pneumonia, or stroke at all 30 nonfederal hospitals in Northeast Ohio. Patients insured by Medicare were used to examine changes in mortality.
Measures: Trends in market share (proportion of patients with the target conditions discharged from a given hospital) and risk-adjusted 30-day mortality.
Results: CHQC identified several hospitals with consistently higher than expected mortality. The five hospitals with the highest mortality tended to lose market share (mean change -0.6%, 95% CI -1.9-0.6), but this was not significant. The only outlier hospital with a large decline in market share had declining volume for 2 years before being declared an outlier. Risk-adjusted mortality declined only slightly at hospitals classified by us as "below average" (-0.8%; 95% CI, 2.9-1.8%) or "worst" (-0.4%; 95% CI -2.3-1.7). However, risk-adjusted mortality at one hospital changed from consistently above expected to consistently below expected shortly after first being declared an outlier.
Conclusion: Despite CHQC's strengths, identifying hospitals with higher than expected mortality did not adversely affect their market share or, with one exception, lead to improved outcomes. This failure may have resulted from consumer disinterest or difficulty interpreting CHQC reports, unwillingness of businesses to create incentives targeted to hospitals' performance, and hospitals' inability to develop effective quality improvement programs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.MLR.0000064640.66138.9A | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background And Objectives: Generic formulations of glatiramer acetate have been available since 2015 yet remain underprescribed relative to the branded product. We sought to characterize the association between branded glatiramer prescribing in the Medicare program and financial payments from the manufacturer (Teva Pharmaceuticals).
Methods: Using publicly available Medicare Part D and Open Payments data from the Centers for Medicare and Medicaid Services, we evaluated overall utilization from 2012 to 2021 and compared the prevalence, frequency, and magnitude of financial payments made in 2019 to neurologists who prescribed branded and generic versions of glatiramer in 2020.
How charitable giving affects litigation duration? Empirical evidence from China.
PLoS One
December 2024
School of Law, Southwestern University of Finance and Economics, Chengdu, China.
Charitable donations are an important manifestation of corporate social responsibility. Current research focuses on the economic effects of corporate donations while ignoring their legal effects in the litigation field. This paper utilizes litigation and arbitration data from A-share listed companies in Shanghai and Shenzhen from 2008 to 2021 to investigate the impact and mechanism of charitable donations on the litigation duration of listed companies.
View Article and Find Full Text PDFInduction of MASH in three-dimensional bioprinted human liver tissue.
PLoS One
December 2024
University of California, San Diego, La Jolla, California, United States of America.
Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (MASH), is a major risk factor for cirrhosis and hepatocellular carcinoma (HCC) and a leading cause of liver transplantation. MASH is caused by an accumulation of toxic fat molecules in the hepatocyte which leads to inflammation and fibrosis. Inadequate human "MASH in a dish" models have limited our advances in understanding MASH pathogenesis and in drug discovery.
View Article and Find Full Text PDFImmunogenicity and safety of the MF59-adjuvanted seasonal influenza vaccine in non-elderly adults: A systematic review and meta-analysis.
PLoS One
December 2024
Seqirus S.r.l., Monteriggioni (Siena), Italy.
Objective: In Europe, the age indication for the MF59-adjuvanted quadrivalent influenza vaccine (aQIV) has recently been extended from ≥65 to ≥50 years. Considering that the earliest approval of its trivalent formulation (aTIV) in Italy was for people aged ≥12 years, we aimed to systematically appraise data on the immunogenicity, efficacy, and safety of aTIV/aQIV in non-elderly adults.
Methods: A systematic literature review was conducted according to the available guidelines and studies were searched in MEDLINE, Biological Abstracts, Web of Science, Cochrane Library and clinical trial registries.
Behavioral choice of manufacturers, recyclers and customers in Trade-In Programs.
PLoS One
January 2025
Business School, Shanghai Dianji University, Shanghai, Pudong, China.
This study investigates the behavioral choices of manufacturers, recyclers, and customers in Trade-In Programs designed to promote recycling and environmental sustainability. Using a manufacturer-led evolutionary game model, the research explores how factors such as government policies, market demand, financial incentives, and the simplicity of participation impact stakeholder engagement in these programs. Numerical simulations were conducted to analyze the effects of specific parameters on each participants' willingness to participate.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!